Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 9/20 | 0.46 |
| ▸ | MME | P08473 | 2/20 | 0.46 |
| ▸ | CPA1 | P15085 | 1/20 | 0.46 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.46 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18879461 | 0.89 | GRIA1 (0.44) | ACEMMECPA1ACE2GRIA1 | |
| SCHEMBL23135666 | 0.85 | CTSL (0.44) | ACEMMECPA1ACE2GRIA1 | |
| SCHEMBL23026392 | 0.84 | CTSL (0.49) | ACEMMECPA1ACE2GRIA1 | |
| SCHEMBL19700517 | 0.83 | FOLH1 (0.45) | ACEMMECPA1ACE2GRIA1 | |
| SCHEMBL22692612 | 0.80 | CTSL (0.40) | ACEMMECPA1ACE2GRIA1 | |
| SCHEMBL19871860 | 0.78 | OPRD1 (0.39) | ACEMMECPA1ACE2GRIA1 | |
| SCHEMBL21503815 | 0.77 | ACE (0.48) | ACEMMECTSL | |
| SCHEMBL18973012 | 0.77 | MAPT (0.44) | ACEMMECPA1ACE2 | |
| SCHEMBL20970450 | 0.75 | GRIA1 (0.46) | ACEMMECPA1ACE2GRIA1 | |
| SCHEMBL21415384 | 0.71 | GRIA1 (0.46) | GRIA1CTSLOPRD1OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200268898-A1 | GLP-1 RECEPTOR LIGAND MOIETY CONJUGATED OLIGONUCLEOTIDES AND USES THEREOF | IONIS PHARMACEUTICALS, INC. | 2020-08-27 | — | — | US | disclosed |
| US-20190134214-A1 | GLP-1 Receptor Ligand Moiety Conjugated Oligonucleotides and Uses Thereof | ASTRAZENECA AB (SE) | 2019-05-09 | — | — | US | disclosed |
| US-9957504-B2 | Compositions and methods for modulating apolipoprotein (a) expression | IONIS PHARMACEUTICALS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190134214-A1 | GLP-1 Receptor Ligand Moiety Conjugated Oligonucleotides and Uses Thereof | GLP1R, GIPR, GRPR | ACE 3959/4885MME 2366/4885CPA1 885/4885 |
| US-20200268898-A1 | GLP-1 RECEPTOR LIGAND MOIETY CONJUGATED OLIGONUCLEOTIDES AND USES THEREOF | GLP1R, GIPR, GRPR | ACE 3959/4885MME 2366/4885CPA1 885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.